Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2958)	6/23/2010 11:59:40 AM
From: Jibacoa	Respond to of 3722

O.T. Well, Max Plank is finally breaking ground for their new Labs in Jupiter, with completion expected by 2012. They had already a few people working at temporary space at FAU as Scripps did before completion of their Labs last year. And Scripps continues to add more people to their Research Roster in Jupiter.<g> It seems that the Jupiter area is already a good place for Biotechnology Research.<g> palmbeachpost.com Bernard

To: Jibacoa who wrote (2958)	6/23/2010 1:55:57 PM
From: Jibacoa	1 Recommendation Read Replies (1) \| Respond to of 3722

ARWR continues to hold above the support at the $2.20 level.<g> bigcharts.marketwatch.com It announced today the closing of its recent $8.6M offering. Its CEO,Christopher Anzalone,said that he expects that the subsidiaries, Calando and Unidym will now be on a better position to maximize their values and approach potential partnerships from "a position of strength". <g> Calando has already demonstrated that its systemic siRNA delivery and gene silencing in humans works as expected, Unidym has made great progress in the touch panel markets. As mentioned, the ACTAY is $9 But although ARWR has room to run, I will still keep a target at $3.<g> bigcharts.marketwatch.com Bernard